BR112022001710A2 - Moléculas mhc de classe ii e métodos de uso das mesmas - Google Patents

Moléculas mhc de classe ii e métodos de uso das mesmas

Info

Publication number
BR112022001710A2
BR112022001710A2 BR112022001710A BR112022001710A BR112022001710A2 BR 112022001710 A2 BR112022001710 A2 BR 112022001710A2 BR 112022001710 A BR112022001710 A BR 112022001710A BR 112022001710 A BR112022001710 A BR 112022001710A BR 112022001710 A2 BR112022001710 A2 BR 112022001710A2
Authority
BR
Brazil
Prior art keywords
class
amino acid
methods
molecules
hla
Prior art date
Application number
BR112022001710A
Other languages
English (en)
Portuguese (pt)
Inventor
Kenji Sugata
Naoto Hirano
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of BR112022001710A2 publication Critical patent/BR112022001710A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR112022001710A 2019-07-30 2020-07-29 Moléculas mhc de classe ii e métodos de uso das mesmas BR112022001710A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962880501P 2019-07-30 2019-07-30
US202063029114P 2020-05-22 2020-05-22
PCT/IB2020/057173 WO2021019473A1 (en) 2019-07-30 2020-07-29 Mhc class ii molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022001710A2 true BR112022001710A2 (pt) 2022-06-21

Family

ID=74228599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001710A BR112022001710A2 (pt) 2019-07-30 2020-07-29 Moléculas mhc de classe ii e métodos de uso das mesmas

Country Status (12)

Country Link
US (1) US12590139B2 (https=)
EP (1) EP4004034A4 (https=)
JP (1) JP7811540B2 (https=)
KR (1) KR20220052943A (https=)
CN (1) CN114450302A (https=)
AU (1) AU2020322246A1 (https=)
BR (1) BR112022001710A2 (https=)
CA (1) CA3146292A1 (https=)
IL (1) IL290223A (https=)
MX (1) MX2022001210A (https=)
TW (1) TW202116797A (https=)
WO (1) WO2021019473A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3935175A4 (en) 2019-03-04 2023-01-04 University Health Network T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF
BR112022001704A2 (pt) * 2019-07-30 2022-07-05 Univ Health Network Moléculas mhc de classe ii e métodos de uso das mesmas
CN118662607A (zh) * 2023-03-15 2024-09-20 中国科学院上海巴斯德研究所 抑制过激炎性反应的蛋白及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4218987B2 (ja) * 1996-11-13 2009-02-04 明治乳業株式会社 ペプチド免疫療法治療剤
IL157073A0 (en) * 2001-01-24 2004-02-08 Harvard College Therapeutic peptides for demyelinating conditions
GB0107628D0 (en) 2001-03-27 2001-05-16 Avidex Ltd Substances
EP1403283A4 (en) * 2001-06-12 2006-05-10 Greenpeptide Co Ltd TUMOR ANTIGEN
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
CN101001868A (zh) * 2004-06-17 2007-07-18 曼康公司 表位类似物
US20060084116A1 (en) * 2004-09-13 2006-04-20 Xencor, Inc. Analysis of MHC-peptide binding interactions
US20060228758A1 (en) 2004-09-13 2006-10-12 Xencor, Inc. Analysis of MHC-peptide binding interactions
US20100099090A1 (en) 2007-03-05 2010-04-22 Bristol-Mayers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2016135363A1 (es) * 2015-02-23 2016-09-01 Servicio Andaluz De Salud Método de obtención de datos útiles para predecir o pronosticar la transmisión vertical, la cronificación y/o el aclaramiento del virus de la hepatitis c
JP2018528191A (ja) 2015-08-19 2018-09-27 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 抗体を生成する新規な方法
WO2017185169A1 (en) * 2016-04-27 2017-11-02 University Health Network (Uhn) Pept1de-hla complexes and methods of producing same
RU2763798C1 (ru) 2017-12-23 2022-01-11 Рубиус Терапьютикс, Инк. Искусственные антигенпрезентирующие клетки и способы их применения
BR112022001704A2 (pt) 2019-07-30 2022-07-05 Univ Health Network Moléculas mhc de classe ii e métodos de uso das mesmas
US20220291215A1 (en) 2019-07-30 2022-09-15 University Health Network Methods of identifying t cell receptors
CN114502580B (zh) 2019-07-30 2025-10-17 大学健康网络 Mhc ii类分子及其使用方法

Also Published As

Publication number Publication date
WO2021019473A1 (en) 2021-02-04
IL290223A (en) 2022-03-01
EP4004034A1 (en) 2022-06-01
CN114450302A (zh) 2022-05-06
KR20220052943A (ko) 2022-04-28
JP7811540B2 (ja) 2026-02-05
TW202116797A (zh) 2021-05-01
CA3146292A1 (en) 2021-02-04
EP4004034A4 (en) 2023-11-15
US12590139B2 (en) 2026-03-31
JP2022542447A (ja) 2022-10-03
AU2020322246A1 (en) 2022-03-03
MX2022001210A (es) 2022-05-03
US20220275051A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
BR112022001702A2 (pt) Moléculas mhc classe ii e métodos de uso das mesmas
BR112022001710A2 (pt) Moléculas mhc de classe ii e métodos de uso das mesmas
BR112018000477A2 (pt) proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural
CY1122576T1 (el) Ανθρωπινα αντισωματα που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (leg-3), και χρησεις εξ' αυτων
WO2022109339A8 (en) Use of dextramer in single cell analysis
BR112023012432A2 (pt) Composições e métodos para modificação genética de ciita em uma célula
AR060583A1 (es) Anticuerpo de c- kit humanizado
BRPI0111191B8 (pt) moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos
BR112021018236A2 (pt) Bioconjugado de um polissacarídeo de antígeno o4 glicosilado de e. coli covalentemente ligado a uma proteína transportadora, composição, métodos para induzir anticorpos, para vacinar um indivíduo e para produzir um bioconjugado, e, célula hospedeira procariótica recombinante
BRPI0620946A8 (pt) anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
BR112022001704A2 (pt) Moléculas mhc de classe ii e métodos de uso das mesmas
BR112012017124B8 (pt) método para produzir e para purificar um multímero polipeptídico
BRPI0515649B8 (pt) Processo para preparação de composições de anticorpo monoclonal altamente concentradas
BRPI0514680A (pt) produção de anticorpos anti-amilóide beta
BR112021018734A2 (pt) Receptores de células t e métodos de uso destes
BR112021012240A2 (pt) Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich
BR112021017464A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112023002724A2 (pt) Neoantígenos ras e seus usos
MX2022001204A (es) Métodos de identificación de receptores de linfocitos t.
ECSP23024373A (es) Composición para inmunoterapia
BR112022015897A2 (pt) Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v
BR112021017479A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017491A2 (pt) Receptores de células t e métodos de uso dos mesmos
WO2020185796A9 (en) High avidity wt1 t cell receptors and uses thereof